REAL-WORLD EVIDENCE DEMONSTRATES COMPARABLE CLINICAL OUTCOMES OF SWITCHING FROM INSULIN GLARGINE 100 U/ML TO INSULIN GLARGINE 300 U/ML VS INSULIN DEGLUDEC IN T2D PATIENTS

被引：0
|
作者：
Blonde, L. [1 ]
Zhou, F. L. [2 ]
Bosnyak, Z. [3 ]
Westerbacka, J. [3 ]
Gupta, V. E. [4 ]
Sharma, R. K. [4 ]
Bailey, T. S. [5 ]
机构：
[1] Ochsner Med Ctr, Diabet Clin Res Unit, New Orleans, LA USA
[2] Sanofi, Med Affairs, Bridgewater, MA USA
[3] Sanofi, Med Affairs, Paris, France
[4] Accenture, Florham Pk, NJ USA
[5] AMCR Inst, Escondido, CA USA
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
312
引用
收藏
页码：A137 / A138
页数：2
相关论文
共 50 条
  • [1] Real-World Health Outcomes in Patients with T2D Initiating Insulin Glargine 300 U/mL vs. Insulin Glargine 100 U/mL in a Specialist Endocrinology Practice
    Abitbol, Alexander
    Brown, Ruth E.
    Jiandani, Dishay
    Aronson, Ronnie
    [J]. DIABETES, 2017, 66 : A272 - A272
  • [2] Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching from Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)-DELIVER D
    Sullivan, Sean D.
    Bailey, Timothy S.
    Roussel, Ronan
    Zhou, Fang L.
    Bosnyak, Zsolt
    Preblick, Ron
    Westerbacka, Jukka
    Gupta, Rishab
    Blonde, Lawrence
    [J]. DIABETES, 2018, 67
  • [3] Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching From Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)-DELIVER D plus Subgroup Analyses
    Sullivan, Sean D.
    Bailey, Timothy S.
    Roussel, Ronan
    Zhou, Fang L.
    Bosnyak, Zsolt
    Preblick, Ron
    Westerbacka, Jukka
    Gupta, Rishab
    Blonde, Lawrence
    [J]. DIABETES, 2018, 67
  • [4] Improved real-world outcomes for type 2 diabetes patients on basal-bolus insulin therapy switching to insulin glargine 300 U/ml vs. insulin glargine 100 U/ml and insulin Detemir
    Wu, Jasmanda
    Bailey, Timothy S.
    Bosnyak, Zsolt
    Westerbacka, Jukka
    Gupta, Rishab A.
    Menon, Arjun A.
    Nicholls, Charlie
    Blonde, Lawrence
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 416 - 417
  • [5] COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CROATIA
    Bogdanovic, M.
    Fournier, M.
    Vitezic, D.
    [J]. VALUE IN HEALTH, 2018, 21 : S131 - S132
  • [6] COST-UTILITY EVALUATION OF INSULIN GLARGINE (300 U/ML) VERSUS INSULIN GLARGINE (100 U/ML) AND INSULIN DEGLUDEC (100 U/ML) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SERBIA
    Mihajlovic, J.
    Bogdanovic, M.
    Foumier, M.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A481 - A481
  • [7] COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN BULGARIA
    Bogdanovic, M.
    Mihajlovic, J.
    Fournier, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S133 - S133
  • [8] Comparison of pharmacodynamics between insulin glargine 100 U/mL and insulin glargine 300 U/mL in healthy cats
    Saini, N. K.
    Wasik, B.
    Pires, J.
    Leale, D. M.
    Quach, N.
    Culp, W. T. N.
    Samms, R. J.
    Johnson, A. E.
    Owens, J. G.
    Gilor, C.
    [J]. DOMESTIC ANIMAL ENDOCRINOLOGY, 2021, 75
  • [9] Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
    Steinstraesser, A.
    Schmidt, R.
    Bergmann, K.
    Dahmen, R.
    Becker, R. H. A.
    [J]. DIABETES OBESITY & METABOLISM, 2014, 16 (09): : 873 - 876
  • [10] Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation
    Owens, D. R.
    Bailey, T. S.
    Fanelli, C. G.
    Yale, J. -F.
    Bolli, G. B.
    [J]. DIABETES & METABOLISM, 2019, 45 (04) : 330 - 340
12345